A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia

Progress in Neuro-psychopharmacology & Biological Psychiatry
Shahin AkhondzadehSams-Ali Rezazadeh

Abstract

There is considerable incentive to develop new treatment strategies that effectively target cognitive deficits in schizophrenia. One of the theoretically promising novel treatment candidates is acetylcholinesterase inhibitors that increase the synaptic levels of cholinergic, nicotinic, and muscarinic receptor activity. The purpose of this study was to assess the efficacy of donepezil as an adjuvant agent in the treatment of chronic schizophrenia in particular for cognitive impairments. This investigation was a 12-week, double-blind study of parallel groups of patients with stable chronic schizophrenia. Thirty patients were recruited from inpatient and outpatient departments, age ranging from 22 to 44 years. All participants met DSM-IV-TR. diagnostic criteria for schizophrenia. To be eligible, patients were required to have been treated with a stable dose of risperidone as their primary antipsychotic treatment for a minimum period of 8 weeks. The subjects were randomized to receive donepezil (10 mg/day) or placebo, in addition to risperidone (4-6 mg/day). Clinical psychopathology was assessed with Positive and Negative Syndrome Scale (PANSS). Cognition was measured by a cognitive battery. Patients were assessed by a psychiatrist...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 10, 2002·Acta Psychiatrica Scandinavica·G W MacEwanC Wrixon
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Dec 19, 2003·Expert Opinion on Pharmacotherapy·Gustavo C Román, Susan J Rogers
Jan 27, 2004·The International Journal of Neuropsychopharmacology·Onder TuğalAhmet Göğüş
Mar 23, 2005·Biological Psychiatry·Richard S E KeefeMargaret P Poe
Aug 27, 2005·The Psychiatric Clinics of North America·Christopher R Bowie, Philip D Harvey
Oct 4, 2005·Clinical Therapeutics·Joseph PeuskensFlorence Thibaut
Nov 17, 2006·The Journal of Clinical Psychiatry·Philip D Harvey
Jul 13, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard S E KeefeRobert Goldman
Dec 7, 2007·The American Journal of Psychiatry·Susan R McGurkKim T Mueser

❮ Previous
Next ❯

Citations

Sep 8, 2010·Current Psychiatry Reports·Elizabeth HansonChristian Kohler
Sep 4, 2013·The British Journal of Psychiatry : the Journal of Mental Science·Kee-Hong ChoiMatthew M Kurtz
Dec 12, 2012·Expert Opinion on Investigational Drugs·Neelam ThakurathiDavid C Henderson
May 3, 2014·Expert Opinion on Drug Metabolism & Toxicology·David Prvulovic, Barbara Schneider
Aug 12, 2009·Neuroscience and Biobehavioral Reviews·Peter DomeZoltan Rihmer
Jun 23, 2009·Bipolar Disorders·Joseph F Goldberg, K N Roy Chengappa
Jun 12, 2012·Depression Research and Treatment·R Lopes, L Fernandes
Aug 14, 2013·Schizophrenia Research·Celso ArangoStephen R Marder
Apr 23, 2015·Bioorganic & Medicinal Chemistry Letters·Marilia ValliVanderlan da Silva Bolzani
Dec 1, 2017·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Ehsan Moazen-ZadehShahin Akhondzadeh
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Jasvinder SinghMahesh B Jayaram
Oct 17, 2018·Journal of Psychopharmacology·Borja SantosJavier Ballesteros
Dec 24, 2008·Expert Review of Neurotherapeutics·Elizabeth Scarr, Brian Dean
Sep 6, 2021·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·M A MorozovaA G Beniashvili

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here